Is Core Laboratories Inc. (CLB) Overvalued?
We dive into why Core Laboratories Inc. (CLB) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and natural gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, production, and well abandonment. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories Inc. was founded in 1936 and is based in Houston, Texas.
Commentary & Analysis
What You Need to Know About Core Laboratories Inc.'s Q3 Earnings
Core Laboratories Inc.'s fiscal Q3 earnings report was released on Wednesday, July 29. Let's dive in to see if (CLB) missed or beat analyst's expectations.Michael Rose
Why Core Laboratories Inc.’s (CLB) Stock Is Up 5.52%
As of Wednesday, July 22, Core Laboratories Inc.’s CLB share price has surged by 5.52%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Core Laboratories Inc.’s (CLB) Stock Is Up 5.23%
As of Monday, July 13, Core Laboratories Inc.’s CLB share price has surged by 5.23%, which has investors questioning if this is right time to sell.Michael Rose
Why Core Laboratories Inc.’s (CLB) Stock Is Up 5.15%
As of Wednesday, July 01, Core Laboratories Inc.’s CLB share price has surged by 5.15%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | CLB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $562.5 | $1,345.1 | 38% |
|
| Shares Out (Mil) | 46.9 | 69.9 | 46% |
|
| Institutional Ownership | 98.7% | 94.2% | 81% |
|
| Float (Mil) | 45.2 | 59.2 | 45% |
|
| Beta | 1.06 | 0.85 | 64% |
|
| Avg Daily Volume (000s) | 423 | 423 | 57% |
|
| Price Change (52-week) |
(1.0%) | 77.6% | 49% |
|
| Growth | CLB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 1.6% | 11.9% | 22% |
|
| Net Income (5yr) | 18.2% | 18.0% | 70% |
|
| EPS (5yr) | 18.0% | 18.0% | 64 |
|
| Dividends (5yr) | (32.2%) | 0.0% | 54% |
|
| Cash Flow (5yr) | 5.9% | 8.6% | 68% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | $0.153 | $0.457 | $0.703 | |
| Month Ago EPS | $0.153 | $1.820 | $2.015 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 2 | |
| Three Months Ago EPS | $0.180 | $1.820 | $2.015 | |
| Year/Year Chg | 18.6% | (27.5%) | na | |
| Financials | CLB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $519 | $1,115 | 41% |
|
| Net Income (TTM) (Mil) | $24 | $32 | 50% |
|
| EPS (TTM) | $0.528 | $0.500 | 54% |
|
| Operating Cash Flow (TTM) (Mil) | $28 | $192 | 43% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | $16 | 31% |
|
| Long-Term Debt (Q1) (Mil) | $153 | $328 | 47% |
|
| Enterprise Value (Q1) (Mil) | $637 | $2,002 | 36% |
|
| Valuation | CLB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.06 | 1.69 | 52% |
|
| P/E | 23.5 | 26.3 | 61% |
|
| Dividend Yield | 0.3% | 0.0% | 61% |
|
| PEG (5yr hist) | 1.3 | 1.2 | 56% |
|
| Ratios | CLB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 19.5% | 27.8% | 20% |
|
| Net Margin | 4.7% | 2.9% | 47% |
|
| ROA | 4.1% | 2.8% | 67% |
|
| ROE | 9.1% | 5.3% | 54% |
|
| Liabilities to Assets | 52.5% | 51.8% | 45% |
|
| F-Score | 6 | 5 | 67% |
|
Core Laboratories Inc. did not pass any screens on 9/15/2026.
